Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Concomitant Lewy body pathology exacerbated cognitive decline in Alzheimer's disease. (Nature Communications) Blocking ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening ...

Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO ...

‘Early treatment with high-efficacy #multiplesclerosis drugs like ocrelizumab, rituximab, or natalizumab can improve ...

Ocrelizumab also helps to prevent Multiple Sclerosis (MS) relapses. The new method has been used at Swansea Bay University ...